Geoffrey Joyce, PhD
Chair, Department of Pharmaceutical and Health Economics
Pharmaceutical and Health EconomicsCurriculum Vitae
- Web Site
- 635 Downey Way, Los Angeles, CA 90089
- VPD 412D
- (213) 821-7958
- (213) 740- 3460
CURRENT FUNDED RESEARCH
Principal Investigator “The Impact of Prior Authorization”. American Medical Association, June 2016- February 2017.
Principal Investigator “Integrating Clinical Pharmacy Services in Safety-Net Clinics”. Centers for Medicare and Medicaid Services, July 2012- June 2016.
Co-Investigator (Goldman, PI) “An Economic and Behavioral Evaluation of Medicare Part D”.
National Institute on Aging (P01AG033559), 2011-2016.
Principal Investigator. Medco/RAND Center for Healthy Action. Medco Health Solutions. May 2009-April 2011.
Principal Investigator. “Extreme Cost-Sharing for Specialty Drugs and Their Association with Medical Service Use.” Amgen, Inc., November 2008 – October 2009.
Principal Investigator. “The Value of Broad Pharmaceutical Formularies: A Replication-of-Failure Analysis.” Janssen Pharmaceuticals, November 2008 – October 2009.
Principal Investigator (with D. Goldman). "Improving Pharmacy Benefit Design". National Institute on Aging, Grant Number: 1R01AG029514 - 01A2. August 2008 – July 2012.
Principal Investigator. “The Social Benefits of More Generous Medicaid Formulary Policies for Antipsychotics.” Janssen Pharmaceuticals, December 2007 – December 2009.
PAPERS SUBMITTED FOR PUBLICATION & CURRENT RESEARCH
Joyce G, Henkhaus L, Gascue L, Zissimopoulos J. Changes in Generic Drug Pricing and the Impact on Patients.
Trish E, Xu J, Joyce G. The Changing Composition of the Catastrophic Coverage Phase.
Joyce G, Zhou B, Ribero R, Van Deen W, Seabury S. The Clinical Consequences of Prior Authorization – The Case of Novel Anticoagulants.
Van Deen W, Zhou B, Ribero R, Seabury S, Joyce G. Expanding Use of Prior Authorization in Medicare Part D.
Xie R, Goldman D, St. Clair P, Joyce G. Differences in Medication Adherence by Race, Ethnicity and Socioeconomic Status.
Buttorf C, Xu Y, Joyce G. Variation in Generic Drug Use in Medicare Part D.
Director of Health Policy, Leonard D. Schaeffer Center for Health Policy & Economics, 2009-
Research Associate, National Bureau of Economic Research, 2011-
Senior Economist, RAND Corporation, 2005-2009
Economist, RAND Corporation, 2002-2005
Associate Economist, RAND Corporation, 2000-2002
Consultant, RAND Corporation, 1997-2000
Research Scientist, VA San Diego and University of California San Diego, 1999-2000
Research Analyst, National Bureau of Economic Research (NBER), 1989-1995
Associate Professor and Chair, Department of Pharmaceutical & Health Economics, University of Southern California, 2009-
Professor, Pardee RAND Graduate School, 2006-2009
Adjunct Associate Professor, UCLA School of Public Health, 2005-
Co-Director, UCLA/RAND Health Services Research Training Program, 2004-
Visiting Professor, UCLA School of Public Health, 2004
Adjunct Lecturer, USC School of Policy, Planning & Development, 2002-2005, 2009
Adjunct Lecturer, Cornell University School of Industrial & Labor Relations, 1993-1995
Adjunct Lecturer, Hunter College (CUNY), Department of Economics, 1992-1995
Postdoctoral Fellow, UCLA/RAND, 1995-1997
Ph.D. in Economics, City University of New York, December 1995
MPP, Ford School of Public Policy, University of Michigan, December 1988
B.A. in Economics and Political Science, Connecticut College, May 1983
HONORS, FELLOWSHIPS AND AWARDS
Medal Award, RAND, 2009.
President's Award, RAND, 2007-2008.
Career Development Award, UCLA Claude D. Pepper Center (OAIC), 2003-2006.
Medal Award, RAND, 2006
Exceptional Reviewer, Medical Care 2003-2004.
Medal Award, RAND, 2004
Agency for Health Care Policy Research (AHCPR) Postdoctoral Fellowship, 1995-1997.
Health Care Financing Administration (HCFA) Dissertation Fellowship, 1994-1995.
Gilleece Fellowship, CUNY Graduate Center, 1991-1995.
Who's Who Among Students in American Colleges and Universities, 1995 Edition.
Public Service Fellowship, University of Michigan, 1986-1987.
Referee: Journal of Health Economics, Health Services Research, Journal of the American Medical Association, New England Journal of Medicine, Canadian Medical Journal, Medical Care, Health Affairs, Inquiry, Medical Care Research and Review, American Journal of Managed Care, Archives of General Psychiatry, Journal of the Operational Research Society, Journal of Acquired Immune Deficiency Syndrome, Journal of Disease Management, American Journal of Pharmacy Benefits.
Consultant: Substance Abuse and Mental Health Services Administration (SAMHSA)
RECENT JOURNAL ARTICLES
Van Nuys K, Joyce G, Ribero R and Goldman D. Frequency and Magnitude of Copayments Exceeding Prescription Drug Costs. Journal of the American Medical Association, 2018.
Carrera M, Goldman D, Joyce G, Sood N. Do Physicians Respond to the Costs and Cost-sensitivity of Their Patients? American Economic Journal: Economic Policy, 2018.
Arora S, Sood N, Terp S, Joyce G. The Price May Not Be Right. The Value of Comparison Shopping for Prescription Drugs. American Journal of Managed Care, 2017.
Trish E, Ginsberg P, Gascue L and Joyce G. Physician Reimbursement in Medicare Advantage. JAMA Internal Medicine, 2017, doi:10.1001/jamainternmed.2017.2679.
Joyce G, Sood N. Why Medicare Price Negotiation is the Wrong Prescription for Rising Drug Spending: Response to Rena Conti. Journal of Policy Analysis and Management, 2016, DOI:10.1002/pam.21937.
Zissimopoulos J, Barthold D, Brinton R, Joyce G. Sex and Race Differences in the Association of Statin Use and Incidence of Alzheimer’s Disease. JAMA Neurology, 2016. doi:10.1001/jamaneurol.2016.3783.
Trish E, Xu J, Joyce G. Medicare Beneficiaries Face Growing Out-of-Pocket Burden for Specialty Drugs While in the Catastrophic Coverage Phase. Health Affairs, 2016; 35(9): 1564-1571.
Joyce G, Sood N. Why Medicare Price Negotiation is the Wrong Prescription for Rising Drug Spending. Journal of Policy Analysis and Management, 2016, DOI: 10.1002/pam.21935.
Shin J, Joyce G, McCombs J. Outcomes Associated with Primary and Secondary Non-adherence to Cholesterol Medications. Am J Pharm Benefits, 2016; 8(2): 54-60.